Aralez Pharmaceuticals Inc. (ARLZ) Shares Bought by Ballentine Partners LLC
Ballentine Partners LLC boosted its holdings in shares of Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) by 166.7% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 80,000 shares of the company’s stock after purchasing an additional 50,000 shares during the period. Ballentine Partners LLC owned approximately 0.12% of Aralez Pharmaceuticals worth $183,000 as of its most recent filing with the SEC.
A number of other institutional investors have also modified their holdings of ARLZ. GSA Capital Partners LLP grew its position in Aralez Pharmaceuticals by 88.5% during the 2nd quarter. GSA Capital Partners LLP now owns 541,795 shares of the company’s stock worth $731,000 after purchasing an additional 254,400 shares during the last quarter. Intrinsic Edge Capital Management LLC purchased a new position in Aralez Pharmaceuticals during the 2nd quarter worth $270,000. Brown Advisory Securities LLC purchased a new position in Aralez Pharmaceuticals during the 3rd quarter worth $394,000. KCG Holdings Inc. purchased a new position in Aralez Pharmaceuticals during the 1st quarter worth $310,000. Finally, Salzhauer Michael grew its position in Aralez Pharmaceuticals by 4.5% during the 2nd quarter. Salzhauer Michael now owns 106,293 shares of the company’s stock worth $144,000 after purchasing an additional 4,600 shares during the last quarter. 23.92% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at https://www.dailypolitical.com/2017/11/13/aralez-pharmaceuticals-inc-arlz-shares-bought-by-ballentine-partners-llc.html.
Shares of Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) traded down $0.21 during trading on Monday, reaching $1.70. 953,200 shares of the company’s stock traded hands, compared to its average volume of 883,865. Aralez Pharmaceuticals Inc. has a 52 week low of $0.95 and a 52 week high of $5.49. The company has a current ratio of 1.00, a quick ratio of 0.92 and a debt-to-equity ratio of 4.64.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last issued its earnings results on Thursday, November 9th. The company reported ($0.37) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.02. The business had revenue of $24.30 million for the quarter, compared to the consensus estimate of $22.87 million. Aralez Pharmaceuticals had a negative net margin of 112.89% and a negative return on equity of 118.13%. The business’s quarterly revenue was up 78.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.32) earnings per share. research analysts forecast that Aralez Pharmaceuticals Inc. will post -1.6 EPS for the current year.
Separately, Chardan Capital lowered their price objective on shares of Aralez Pharmaceuticals from $5.50 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, August 10th.
About Aralez Pharmaceuticals
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Want to see what other hedge funds are holding ARLZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ).
Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.